Dr. McGregor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6328- Is this information wrong?
Summary
- Dr. Bradley McGregor is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Tufts University School of Medicine and has been in practice 13 years. He specializes in genitourinary oncology and hematologic oncology.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2010- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2022 - Present
CA State Medical License 2012 - Present
MA State Medical License 2016 - 2025
NH State Medical License 2023 - 2025
ME State Medical License 2022 - 2024
CT State Medical License 2022 - 2024
VT State Medical License 2022 - 2024- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
- Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Start of enrollment: 2019 Nov 27
Publications & Presentations
PubMed
- Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez, David D Yang, Abhishek Tripathi, Jacqueline M Kilar, Meredith Flynn, Brianna May...> ;Cancer Immunology Research. 2024 Mar 29
- Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.Renée Maria Saliby, Chris Labaki, Tejas R Jammihal, Wanling Xie, Maxine Sun, Valisha Shah, Eddy Saad, M Harry Kane, Soki Kashima, Katherine Sadak, Talal El Zarif, Deep...> ;Cancer Cell. 2024 Mar 22
- One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.Berg, S., McGregor, B.> ;Current Treatment Options in Oncology. 2024 Feb 1
- Join now to see all
Journal Articles
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Press Mentions
Fewer Adverse Effects with SBRT in Localized Prostate Cancer?February 21st, 2023- Is a Diet Higher in Plant-Based Foods Associated with a Lower Risk of Prostate Cancer Progression and Recurrence?February 17th, 2023
- Some Prostate Cancer Patients Benefit From More ADT, Not Less, Data ShowSeptember 12th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
